IASLC News

Timely and relevant thoracic oncology news brought to you by the only truly global association dedicated to the multidisciplinary study of lung cancer.
ILCN News
ILCN

The IASLC Lung Cancer News (ILCN) is the IASLC's official news medium for thoracic oncology specialists around the globe. ILCN provides its international audience with timely and relevant lung cancer news on topics across specialties and interests, such as novel clinical trial design and statistics, overcoming barriers to NGS testing, tobacco control and smoking/vaping cessation, patient-driven research, patient communication and care delivery during COVID, and more. Only the IASLC—the only international association dedicated to the study of lung cancer—can bring you multidisciplinary nuanced perspectives on daily clinical conundrums and the latest novel research by the true experts in the field.

Understanding Treatment Options and Resistance in EGFR-positive NSCLC

Unfortunately, the inevitability of therapeutic resistance is always looming for patients with EGFR-mutated lung cancer, regardless of PD-1/PD-L1 status. Dr. Karen Reckamp—together with Drs. Ibiaya Dagogo-Jack, Ticiana Leal, and Daniel Tan, as well as patient advocate Sarah Christ—talks through a patient case, exploring all facets of the care continuum for this population. Beginning with discussion of biomarker testing and next-generation sequencing and moving through various opinions on use of whole-brain radiation therapy, combination chemotherapy, first-/second-generation TKIs, and/or osimertinib (depending on region) to other still unidentified mechanisms of resistance to EGFR TKI treatment and ongoing trials looking at novel therapeutic strategies. The ultimate goals of prolonging progression-free survival in the frontline setting and having patients living longer and better lives are reinforced in this forum. Although the patient on the case went on to the ORCHARD trial, each expert weighs in with their individual considerations for potential care paths, based on region and on emerging data.

Meeting News

WCLC 2020 News Image

The IASLC World Conference on Lung Cancer 2020 took place on January 28-31, 2021. ILCN brings together the highlights of the meeting, including special discussions by experts and advocates in the field of lung cancer. These exclusive recordings are available for viewing in the WCLC 2020 News Theater. Browse the landing page or download the special ILCN WCLC 2020 PDF Edition available in English, Spanish, Japanese, and Mandarin translations for meeting highlights and more. 

PACIFIC-R: Findings Reflect Clinical Reality of Consolidation Therapy in Stage III NSCLC

European Lung Cancer Virtual Congress image

European Lung Cancer Virtual Congress News 

CheckMate 9LA Combination Effective in Advanced NSCLC Despite PD-L1 Expression, TMB Status

European Lung Cancer Virtual Congress image

European Lung Cancer Virtual Congress News 

Olaparib Maintenance Did Not Improve PFS, OS in Platinum-Sensitive NSCLC

European Lung Cancer Virtual Congress image

European Lung Cancer Virtual Congress News 

World Conference on Lung Cancer 2020 News

World Conference on Lung Cancer 2020 News Flipbook Cover Image

Explore all WCLC News Articles.

North American Conference on Lung Cancer 2020 News

NorthAmerican_2020_DailyNews_v7-1-VerticalTeaser

The publication of NACLC 2020

Liquid Biopsy 2020 News

Liquid Biopsy 2020

The publication of Liquid Biopsy 2020

Press releases_2017 opening press conference

For The Media

If you are a member of the media looking for more information about an IASLC-related event or program, please reach out to our media contacts.

IASLC News_landing_Communications Committee box

Communications Committee

Comprising 30 members from around the world and across all areas of lung cancer patient care, including advocacy, the Communications Committee is eager to spotlight IASLC's programs and resources, as well as engage with members about important topics.

Creating Community…
Connect with IASLC and keep up-to-date with our latest news, stories, and insights.

Facebook

AstraZeneca logo
Amgen logo high res

 

Daiichi Sankyo Logo
The IASLC and ILCN would like to thank AstraZeneca and Daiichi Sankyo for their support.